Publication

Video

Supplements and Featured Publications

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Volume1
Issue 1

Dr. Flinn on the Utility of Tafasitamab in Relapsed/Refractory DLBCL

Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).

Ian W. Flinn, MD, PhD, director of Lymphoma Research at Sarah Cannon Research Institute, and the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology and TriStar Centennial Medical Center, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).

Tafasitamab would be considered for any patient with DLBCL who has relapsed and is not suitable for other therapies, says Flinn.

CAR T-cell therapy is a very aggressive treatment option; to receive CAR T cells, patients must be almost as fit as they would need to be to undergo a stem cell transplant. The same almost holds true for patients to receive polatuzumab vedotin (Polivy), which is usually given in combination with bendamustine and rituximab (Rituxan), adds Flinn. In order to be a candidate to receive that combination, patients must have a good hematologic function.

For some patients,that is not a realistic scenario. For example, they could have cytopenias or have previously received multiple chemotherapies, and giving more chemotherapy is not an appropriate approach for them, says Flinn.

As such, tafasitamab, in combination with lenalidomide (Revlimid), is a very appropriate treatment option for that group of patients, concludes Flinn.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity